Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220917 · ClinicalTrials.gov registry record
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
A clinical trial of Type2 Diabetes and Renal Disease, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 781,430
- Enrollment target
- 1
- Study location
NCT05220917 is a study of Type2 Diabetes and Renal Disease that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 781,430 participants, above the 8,751-participant average among 20 other Type2 Diabetes trials with a reported enrollment target (8830% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05220917, a study of Type2 Diabetes and Renal Disease, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 781,430 participants
- Enrollment target
- 1
- Study location
Study Summary
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).
Conditions Studied
Interventions
- DRUG SGLT2 inhibitor
- DRUG DPP-4 inhibitor
- DRUG GLP-1RA
- DRUG 2nd generation SU
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 781,430 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2026-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05220917
The ClinicalTrials.gov registry entry for NCT05220917 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 781,430 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 8,751-participant average among 20 other Type2 Diabetes trials with a reported enrollment target (8830% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type2 Diabetes appearing as the primary indexed condition, and to 4 interventions - of which SGLT2 inhibitor is the first listed.
NCT05220917 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05220917 about?
NCT05220917 is a clinical study titled "Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study". To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-...
What is the current status of trial NCT05220917?
This trial is currently active not recruiting. The enrollment target is 781,430 participants. The study started on 2021-08-01. Estimated completion is 2026-07-01.
What conditions does trial NCT05220917 study?
This clinical trial studies the following conditions: Type2 Diabetes, Renal Disease, Cardiovascular Events.
What interventions are being tested in trial NCT05220917?
The interventions under investigation include: SGLT2 inhibitor (DRUG), DPP-4 inhibitor (DRUG), GLP-1RA (DRUG), 2nd generation SU (DRUG).
Who is sponsoring clinical trial NCT05220917?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05220917 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes
RECRUITING · NA
-
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
RECRUITING · Early Phase 1
-
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
RECRUITING
-
Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
RECRUITING
-
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
ACTIVE NOT RECRUITING · Phase 4
-
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.